AirCurve 10 VAuto from ResMed Inc. - bilevel device quietly anchors sleep-apnea revenue

By Nora Whitfield, ad hoc news Bestsellers & Flagships Desk. Reviewed July 06, 2026, 12:45 AM ET. Details in the imprint.

AirCurve 10 VAuto sits on a nightstand like a compact matte?gray box, its color screen glowing softly as a patient scrolls through settings before bed. The bilevel PAP device is one of ResMed Inc.'s go?to options in US sleep labs for people who simply can't tolerate fixed?pressure CPAP.

What AirCurve 10 VAuto actually does

At its core, AirCurve 10 VAuto is a bilevel positive airway pressure system that automatically adjusts inspiratory and expiratory pressures to keep a patient's airway open while making exhalation easier. Official ResMed materials describe it as a device that uses AutoSet algorithms to tailor pressure on a breath?by?breath basis.

Unlike standard CPAP units that deliver one continuous pressure, the AirCurve 10 VAuto lets clinicians set separate minimum and maximum pressures, with the system floating between them based on detected events such as flow limitation, snoring, or apnea. The product information brochure lists a pressure range from 4 to 25 cm H2O, which is broad enough to cover severe obstructive sleep apnea and many overlapping respiratory conditions.

Designed around comfort and adherence

One sleep technician in Phoenix described watching a patient visibly relax as the device eased off during exhalation; the man went from fighting the airflow to breathing in rhythm within minutes. That detail matters, because ResMed builds the AirCurve 10 VAuto specifically for patients who need higher pressures but struggle with comfort.

ResMed's literature highlights features such as Easy?Breathe waveform and expiratory pressure relief (EPR) to make inhaling and exhaling feel more natural. The US product overview notes that the AirCurve 10 VAuto also includes an integrated humidifier and optional ClimateLineAir heated tubing to reduce dryness and congestion, a common complaint among PAP users.

US availability and pricing

From a US consumer perspective, AirCurve 10 VAuto is a prescription?only device sold through durable medical equipment (DME) providers rather than directly from ResMed. Public pricing guides, such as those compiled by Sleep Foundation and online DMEs, typically quote retail prices in the $1,600 to $2,000 range for the machine with humidifier, before insurance coverage.

Medicare and major commercial insurers often categorize the AirCurve 10 VAuto under bilevel PAP HCPCS codes such as E0470 or E0471, with reimbursement tied to documented sleep?apnea severity and adherence. The Centers for Medicare & Medicaid Services local coverage determinations detail how bilevel devices are covered when CPAP fails or higher pressures are clinically necessary.

Technical specs that matter to clinicians

For sleep physicians, the draw is in the algorithms and data, not just the hardware. AirCurve 10 VAuto uses ResMed's AutoSet technology to respond to subtle changes in breathing, including flow limitation that precedes full apnea. ResMed explains that AutoSet continuously monitors the inspiratory flow to adjust pressure while minimizing unnecessary increases.

The device logs detailed usage and efficacy data, which clinicians access via SD card or through ResMed's connected platform when paired with cellular modules. The AirView portal lets providers monitor nightly usage, apnea?hypopnea index, leak rates, and pressure curves across multiple devices.

Real?world use: who gets AirCurve 10 VAuto

In practice, AirCurve 10 VAuto often shows up as the second?line choice for obstructive sleep?apnea patients who either fail CPAP or need very high pressures. Sleep specialist Dr. Atul Malhotra, who has worked with ResMed on research, has repeatedly emphasized that bilevel devices can boost comfort and adherence at higher pressures, although he typically speaks in broader terms and not only about one product.

ResMed's documentation positions the AirCurve 10 VAuto specifically for patients with obstructive sleep apnea with or without concomitant COPD or hypoventilation, as long as they do not require backup rate modes reserved for more advanced ventilators. The indication sheet lists use for “obstructive sleep apnea patients weighing more than 30 kg”, which covers most adult users.

Comfort hardware: humidification and tubing

Beyond the pressure algorithms, the physical design of AirCurve 10 VAuto leans heavily on integrated comfort. The device shares the same basic chassis as ResMed's AirSense series, including a water chamber that slides into the side of the unit with a firm click and clear fill lines that are easy to see even in dim bedroom light. The ClimateLineAir heated tubing option is designed to keep condensation from forming in the hose, which helps avoid the "rainout" effect many PAP users complain about.

ResMed's marketing materials for clinicians emphasize adjustable humidification levels and automatic climate control mode. Patients who describe waking up with a dry nose or sore throat on unheated CPAP often report less irritation when humidity and tube temperature are set correctly. Those are simple dials on the AirCurve 10 VAuto interface, accessible through the front?facing knob and screen.

Digital layer: data for patients and providers

For tech?savvy patients, the device works with ResMed's myAir app ecosystem when the hardware is configured with compatible communications modules. ResMed promotes myAir as a way for users to see nightly scores, events, and mask?seal statistics in a smartphone dashboard, which can nudge behavior toward better adherence via simple feedback.

On the clinician side, AirCurve 10 VAuto slots into larger data strategies around chronic disease management. The US business model now counts recurring revenue not just from devices themselves, but also from data?enabled care programs and cloud platforms such as AirView. For investors, those recurring software and service streams sit alongside the physical PAP hardware in ResMed's earnings presentations.

Where AirCurve 10 VAuto sits in ResMed's line?up

Inside ResMed's portfolio, AirCurve 10 VAuto is one of several bilevel and advanced therapy devices, sitting next to models like AirCurve 10 ASV for central sleep apnea and servo?ventilation and specialized versions for COPD and neuromuscular disease. The professional portfolio page lists the different AirCurve 10 variants by indication and mode, underscoring that VAuto is aimed squarely at obstructive sleep apnea with auto?adjusting bilevel support.

For US DMEs, stocking AirCurve 10 VAuto is partly about having a reliable mid?range bilevel option from a dominant brand. ResMed and its rival Philips control much of the PAP market, and ResMed's supply stance became particularly important after Philips' major recall in 2021. A resilient bilevel lineup helped ResMed capture demand from patients and providers who needed alternatives.

Manufacturing and regulatory context

ResMed Inc., headquartered in San Diego, runs a global manufacturing and supply chain for its PAP devices, with regulatory approvals across major markets including the US, Europe, and Asia. The company's most recent Form 10?K filed with the SEC describes its sleep and respiratory care segment as the main revenue driver, built around PAP devices, masks, and related accessories.

AirCurve 10 VAuto itself appears in device listings and technical documentation as a cleared product under US Food and Drug Administration rules for non?invasive ventilatory support, though not as a full life support ventilator. The FDA database shows multiple ResMed clearances in the respiratory device class, giving clinicians and hospital purchasers confidence that the hardware and software have passed formal review.

Investor lens: why this device matters

For retail investors, the key point is that AirCurve 10 VAuto is not a flashy consumer gadget; it is a workhorse clinical device feeding into ResMed's core sleep?apnea revenue stream. Bilevel units like this sit in the higher?priced tier of PAP therapy and are used in patients with more complex needs, which can translate to higher average selling prices and more intensive follow?up.

ResMed Inc. stock (NYSE: RMD) is widely covered by Wall Street analysts as a sleep? and respiratory?care play tied to rising diagnosis rates for obstructive sleep apnea and chronic respiratory disease. While management avoids highlighting single products, devices such as AirCurve 10 VAuto collectively underpin the company's recurring equipment and data?driven service revenue.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.